Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
dc.identifier.issn
dc.identifier.doi
10.1093/annonc/mdu473
dc.identifier.other
dc.description.volume
26
dc.description.issue
1
JAN
JAN
Publisher
OXFORD UNIV PRESS
DOI
10.1093/annonc/mdu473
Abstract
This letter criticize the design of ACTS-CC trial
patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.
patients received adjuvant oral fluoropyrimidine therapy without oxaliplatin. Authors believe that oxaplatin should have been a part of the treatment in both arms.